PDS Biotechnology Corporation logo

PDSB

PDS Biotechnology Corporation

$5.11

Earnings Summary

Revenue
$0Mn
Net Profits
$-8.47Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

PDS Biotechnology Corporation’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, PDS Biotechnology Corporation has generated NaN% jump in its revenue since last 3-months.

Net Profits:

PDS Biotechnology Corporation’s net profit fell -177.95% since last year same period to $-8.47Mn in the Q1 2022. On a quarterly growth basis, PDS Biotechnology Corporation has generated -34.08% fall in its net profits since last 3-months.

Net Profit Margins:

PDS Biotechnology Corporation’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, PDS Biotechnology Corporation has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the PDS Biotechnology Corporation post its latest quarter earnings

EPS Estimate Current Quarter
-0.28
EPS Estimate Current Year
-0.28

Highlights

EPS Estimate Current Quarter:

PDS Biotechnology Corporation’s earning per share (EPS) estimates for the current quarter stand at -0.28 - a -27.27% fall from last quarter’s estimates.

EPS Estimate Current Year:

PDS Biotechnology Corporation’s earning per share (EPS) estimates for the current year stand at -0.28.

Key Ratios

Key ratios of the PDS Biotechnology Corporation post its Q1 2022 earnings

Earning Per Share (EPS)
-0.32
Return on Assets (ROA)
-0.27
Return on Equity (ROE)
-0.44
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

PDS Biotechnology Corporation’s earning per share (EPS) fell -128.57% since last year same period to -0.32 in the Q1 2022. This indicates that the PDS Biotechnology Corporation has generated -128.57% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. PDS Biotechnology Corporation’s return on assets (ROA) stands at -0.27.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. PDS Biotechnology Corporation’s return on equity (ROE) stands at -0.44.

Dividend Per Share (DPS):

PDS Biotechnology Corporation declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.22
-0.32
-45.45%

Company Information

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.

Organisation
PDS Biotechnology Corporation
Headquarters
Florham Park, New Jersey, United States
Employees
15
Industry
Biotechnology
CEO
Frank Bedu-Addo